Risk of Suicidal Behavior With Use of Efavirenz: Results from the Strategic Timing of Antiretroviral Treatment Trial.

about

Risk of Suicidal Behavior With Use of Efavirenz: Results from the Strategic Timing of Antiretroviral Treatment Trial.

Item

http://www.wikidata.org/entity/Q52655906

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Risk of Suicidal Behavior With ...... ntiretroviral Treatment Trial.

@en

Risk of Suicidal Behavior With ...... ntiretroviral Treatment Trial.

@nl

type

Item

label

Risk of Suicidal Behavior With ...... ntiretroviral Treatment Trial.

@en

Risk of Suicidal Behavior With ...... ntiretroviral Treatment Trial.

@nl

prefLabel

Risk of Suicidal Behavior With ...... ntiretroviral Treatment Trial.

@en

Risk of Suicidal Behavior With ...... ntiretroviral Treatment Trial.

@nl

P1476

Risk of Suicidal Behavior With ...... ntiretroviral Treatment Trial.

@en

P2093

Alejandro Arenas-Pinto

http://www.w3.org/2001/XMLSchema#string

Birgit Grund

http://www.w3.org/2001/XMLSchema#string

Claudia Afonso

http://www.w3.org/2001/XMLSchema#string

Dalibor Sedlacek

http://www.w3.org/2001/XMLSchema#string

David A Cooper

http://www.w3.org/2001/XMLSchema#string

Esteban Martinez

http://www.w3.org/2001/XMLSchema#string

Eynat Kedem

http://www.w3.org/2001/XMLSchema#string

INSIGHT START study group

http://www.w3.org/2001/XMLSchema#string

Juan Sierra-Madero

http://www.w3.org/2001/XMLSchema#string

Julie Fox

http://www.w3.org/2001/XMLSchema#string

P2860

Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data.

No Evidence of an Association Between Efavirenz Exposure and Suicidality Among HIV Patients Initiating Antiretroviral Therapy in a Retrospective Cohort Study of Real World Data.

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.

Epidemiology and treatment of depression in patients with chronic medical illness.

Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.

Geographical and temporal variations in the prevalence of mental disorders in suicide: Systematic review and meta-analysis.

Adoption of national recommendations related to use of antiretroviral therapy before and shortly following the launch of the 2013 WHO consolidated guidelines.

Comparative Safety and Neuropsychiatric Adverse Events Associated With Efavirenz Use in First-Line Antiretroviral Therapy: A Systematic Review and Meta-Analysis of Randomized Trials.

P31

scholarly article

P356

10.1093/CID/CIY051

http://www.w3.org/2001/XMLSchema#string

P407

English

P50

Christine Katlama

P577

2018-03-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29538636

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

6051455

http://www.w3.org/2001/XMLSchema#string